The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer.
 
Afsaneh Barzi
Consulting or Advisory Role - bioTheranostics; Merrion
 
Sang K Cho
No Relationships to Disclose
 
Joel W Hay
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Fang-Shu Ou
No Relationships to Disclose
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst)
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; Merck Sharp & Dohme
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Genentech/Roche; Glenmark; Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly; Lilly (Inst); Merck (Inst); NCCN; Pfizer; Regeneron; Roche/Genentech (Inst); Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen